Episode 24. ASCO/EHA 2023 Special: Updates on CAR T-cell Therapy in Myeloma
Blood Cancer Talks
00:00
The Disadvantages of Loss of GPRC-5D Expression
In GPRC-5D CAR-T, four out of six patients who progressed after having an initial response had no GPRC. expression at progression. This is in contrast to what the BCMA CAR-T experience where, again, as we described in others, most of the time BCMA may go down but comes back up. And so, I wonder if we may see more sort of escape mutants with loss of GPRC.-5D. But it's a little early. It's probably still speculation. We actually don't have a function at all.
Transcript
Play full episode
